BioCentury | Jan 29, 2019
Distillery Techniques

Imaging

...online Jan. 3, 2019 doi:10.1158/0008-5472.CAN-18-0238 CONTACT: Daniel P. Teufel, Bicycle Therapeutics Ltd., Cambridge, U.K. email: danteufel@cantab.net Sandi...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Ophthalmic disease

...published online Oct. 12, 2018 doi:10.1038/s41467-018-06448-y CONTACT: Sushma-Nagaraja Grellscheid, Durham University, Durham, U.K. email: sushma@cantab.net...
BioCentury | Mar 24, 2017
Clinical News

Triheptanoin: Ph II data

...≥50% reduction in seizure frequency. There was no difference in cognitive function as measured by CANTAB...
...in frequency of seizures, cognitive function as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB...
BioCentury | Feb 3, 2017
Company News

Pro Bono Bio, Spero deal

...antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab...
BioCentury | Mar 17, 2014
Clinical News

Triheptanoin: Phase II started

...as measured by EEG and change in cognitive function using the Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Dec 23, 2013
Clinical News

Metadoxine: Phase IIb data

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Nov 11, 2013
Clinical News

Metadoxine: Completed Phase II enrollment

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Sep 2, 2013
Clinical News

MG01CI: Phase II started

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Mar 18, 2013
Company News

Cantab Biopharmaceuticals, PolyTherics deal

...PolyTherics said it received an undisclosed milestone payment from the Cantab subsidiary of Celtic Pharma Holdings...
...PolyTherics said the milestone was triggered by further progress on a 2010 hematology deal with Cantab...
...VIII product. Cantab develops enhanced versions of marketed, off-patent biologics (see BioCentury, Feb. 1, 2010). Cantab...
BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...delivery company Arecor Ltd. (Cambridge, U.K.); neuromodulation device company Bioinduction Ltd. (Bristol, U.K.); biosimilars company Cantab...
Items per page:
1 - 10 of 180
BioCentury | Jan 29, 2019
Distillery Techniques

Imaging

...online Jan. 3, 2019 doi:10.1158/0008-5472.CAN-18-0238 CONTACT: Daniel P. Teufel, Bicycle Therapeutics Ltd., Cambridge, U.K. email: danteufel@cantab.net Sandi...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Ophthalmic disease

...published online Oct. 12, 2018 doi:10.1038/s41467-018-06448-y CONTACT: Sushma-Nagaraja Grellscheid, Durham University, Durham, U.K. email: sushma@cantab.net...
BioCentury | Mar 24, 2017
Clinical News

Triheptanoin: Ph II data

...≥50% reduction in seizure frequency. There was no difference in cognitive function as measured by CANTAB...
...in frequency of seizures, cognitive function as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB...
BioCentury | Feb 3, 2017
Company News

Pro Bono Bio, Spero deal

...antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab...
BioCentury | Mar 17, 2014
Clinical News

Triheptanoin: Phase II started

...as measured by EEG and change in cognitive function using the Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Dec 23, 2013
Clinical News

Metadoxine: Phase IIb data

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Nov 11, 2013
Clinical News

Metadoxine: Completed Phase II enrollment

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Sep 2, 2013
Clinical News

MG01CI: Phase II started

...TOVA) ADHD score from baseline to 4 hours post-dose; change in Cambridge Neuropsychological Test Battery (CANTAB...
BioCentury | Mar 18, 2013
Company News

Cantab Biopharmaceuticals, PolyTherics deal

...PolyTherics said it received an undisclosed milestone payment from the Cantab subsidiary of Celtic Pharma Holdings...
...PolyTherics said the milestone was triggered by further progress on a 2010 hematology deal with Cantab...
...VIII product. Cantab develops enhanced versions of marketed, off-patent biologics (see BioCentury, Feb. 1, 2010). Cantab...
BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...delivery company Arecor Ltd. (Cambridge, U.K.); neuromodulation device company Bioinduction Ltd. (Bristol, U.K.); biosimilars company Cantab...
Items per page:
1 - 10 of 180